Clinical trial · Interventional
Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli
Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial
NCT02333773CI-TRIAL-00053690IREcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Irreversible electroporation (IRE) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group A
- description
- irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli
- interventionNames
- Procedure: Irreversible electroporation (IRE)
- type
- EXPERIMENTAL
- label
- Group B
- description
- irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli
- interventionNames
- Procedure: Irreversible electroporation (IRE)
- type
- EXPERIMENTAL
- label
- Group C
- description
- irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Liver cancer diagnosed by positive biopsy or non-invasive criteria, * Liver cancer with Portal venous tumor emboli, * Not suitable for surgical resection or transplantation, * Child-Pugh class A,B * Eastern Cooperative Oncology Group (ECOG) score of 0-1, * A prothrombin time ratio \> 50%, * Platelet count \> 80x10\^9/L, * Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure, * Able to comprehend and willing to sign the written informed consent form (ICF), * Have a life expectancy of at least 3 months. Exclusion Criteria: * Cardiac insufficiency, ongoing coronary artery disease or arrhythmia, * Any active implanted device (eg Pacemaker), * Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception, * Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System, * Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.
References
Publications (0)
Data not yet available
No reference posted for this study.